Clinical Trial

TAF to Prevent HBV Reactivation in Cancer Patients

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive cancer patients receiving chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-11-02; most recent amendment 2024-11-09.
Status change: Recruiting → Active, Not Recruiting 2024-11-09
Status change: Not Yet Recruiting → Recruiting 2021-06-29
Trial Details
NCT Number NCT04619082
Lead Sponsor Chiayi Christian Hospital
Collaborators: St. Martin De Porress Hospital, Dalin Tzu Chi General Hospital, National Taiwan University Hospital, Yun-Lin Branch, Chi Mei Medical Hospital
Conditions Hepatitis B Reactivation
Enrollment 102 participants
Start Date 2021-07-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-12